Gynecologic cancers remain an area of huge unmet need. The OncoGenesis biomarker-based cancer assays address this unmet need by providing reliable information that enables the gynecologic physician to identify patients with abnormal lesions that need to be treated before the disease progresses into cancer. Cancer is a complex and multifaceted disease that is caused by multiple genetic and biochemical abnormalities at a cellular level. Thus, the only method to fully characterize the cellular changes required for carcinogenesis, and to define the state of the disease, is to evaluate multiple biomarkers that reflect critical molecular changes associated with cancerous cells. The OncoGenesis paradigm is to quantify a novel panel of biomarkers that are proven to be important in characterizing cervical cancers, and to quantify these biomarkers in relatively non-invasive cervical cytology. These novel biomarkers are embedded in our CerMark cervical cancer screen.
System comprised of six DISCREET BIOMARKERS
Pending FDA clearance in the U.S.